Stephen D. Collins

Stephen D. Collins

Company: Xalud Therapeutics

Job title: Chief Medical Officer


Xalud Therapeutics’ Novel, Immune-Modulatory Platform 4:00 pm

 Sharing our novel immune-modulatory platform Lead program in Phase 2b in OA pain with additional Phase 1b in neuropathic pain and other indications in development XT-150 is an IL-10 variant delivered via plasmid as a non-integrating gene therapy demonstrating an excellent safety profile with compelling data as a novel, long-lasting pain therapeuticRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.